This site is intended for healthcare professionals

Mirikizumab met the primary and all key secondary endpoints in LUCENT-1, phase III induction study to evaluate the efficacy and safety of mirikizumab for moderate to severe ulcerative colitis .

Read time: 1 mins
Last updated:28th Jun 2021
Published:17th Mar 2021
Condition: Ulcerative Colitis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest